Q1 26 EPS
$0.15
BEAT +120.59%
Est. $0.07
Q1 26 Revenue
$132.1M
BEAT +1.69%
Est. $129.9M
vs S&P Since Q1 26
-18.3%
TRAILING MARKET
BVS -18.3% vs S&P 0.0%
Market Reaction
Did BVS Beat Earnings? Q1 2026 Results
Bioventus Inc. Posted a standout first quarter of 2026, with adjusted EPS of $0.15 beating the $0.07 consensus estimate by 120.59% and revenue of $132.09 million edging past the $129.90 million forecast by 1.69%, reflecting 6.6% year-over-year growth… Read more Bioventus Inc. Posted a standout first quarter of 2026, with adjusted EPS of $0.15 beating the $0.07 consensus estimate by 120.59% and revenue of $132.09 million edging past the $129.90 million forecast by 1.69%, reflecting 6.6% year-over-year growth. The most material driver of the upside was a broad-based contribution across all three business segments, headlined by a favorable $4.20 million rebate adjustment in Pain Treatments and sustained U.S. Demand in Surgical Solutions, where Bone Graft Substitutes and Ultrasonics each gained traction. Profitability improved sharply, with Adjusted EBITDA expanding 24% to $23.91 million and Non-GAAP operating margin widening to 15.4% from 14.3% a year earlier. Notably, operating cash flow swung to $8.93 million from an outflow of $19.33 million in the prior-year period, allowing Bioventus to make a discretionary $22.00 million term loan prepayment in late March. Management responded to the momentum by raising full-year Adjusted EPS guidance to $0.75–$0.79 and Cash from Operations guidance to $84.00–$89.00 million, while reaffirming net sales guidance of $600.00–$610.00 million for 2026.
Key Takeaways
- • Favorable $4.2 million rebate benefit from billing process change by a third-party private insurer in Pain Treatments
- • Higher U.S. demand for Bone Graft Substitutes and Ultrasonics in Surgical Solutions
- • Continued commercial effectiveness and sales force execution with EXOGEN Bone Stimulation System
- • Strong international growth of 17.1% driven by Ultrasonics and HA therapies for knee osteoarthritis
- • Net interest expense declined to $4.3 million from $7.5 million due to debt reduction
- • Non-GAAP gross margin expanded to 76.4% from 75.3%
BVS Forward Guidance & Outlook
Bioventus raised full-year 2026 guidance for Adjusted EPS to $0.75–$0.79 (up $0.02 from prior guidance) and Cash from Operations to $84 million–$89 million (up $2 million), driven by accelerated cash flow and faster-than-anticipated debt repayment. The company reaffirmed its 2026 net sales guidance of $600 million to $610 million, reflecting approximately 6%–7% growth.
BVS YoY Financials
Q1 2026 vs Q1 2025, source: SEC Filings
BVS Revenue by Segment
With YoY comparisons, source: SEC Filings
BVS Revenue by Geography
With YoY comparisons, source: SEC Filings
“Our team delivered a strong start to 2026, driven by continued momentum in our core businesses and disciplined execution across our commercial and operational priorities.”
— Rob Claypoole, Q1 2026 Earnings Press Release
BVS Earnings Trends
BVS vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
BVS EPS Trend
Earnings per share: estimate vs actual
BVS Revenue Trend
Quarterly revenue: estimate vs actual
BVS Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $0.07 | $0.15 | +120.59% | $132.1M | +1.69% |
| Q4 25 BEAT FY | $0.22 | $0.24 | +10.75% | $157.9M | +1.91% |
| FY Full Year | — | $0.68 | — | $568.1M | — |
| Q3 25 BEAT | $0.12 | $0.15 | +30.43% | $138.7M | +0.34% |
| Q2 25 BEAT | $0.20 | $0.21 | +6.76% | $147.7M | +1.23% |
| Q1 25 BEAT | $0.02 | $0.08 | +250.88% | $123.9M | +0.95% |